Cyclerion Therapeutics Inc Net Assets
Cyclerion Therapeutics Inc net assets. Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has net assets worth $5.09 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.93 Million) and total liabilities ($1.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Cyclerion Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.09 Million |
| % of Total Assets | 73.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -81.17% |
| 10-Year Change | N/A |
| Growth Volatility | 28.71 |
Net Assets of Cyclerion Therapeutics Inc (2016–2025)
Net assets of Cyclerion Therapeutics Inc from 2016 to 2025. This chart illustrates how Cyclerion Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Cyclerion Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual net assets of Cyclerion Therapeutics Inc from 2016 to 2025. For live market cap and overall valuation, see CYCN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.09 Million | +2.66% |
| 2024-12-31 | $8.85 Million | -21.60% |
| 2023-12-31 | $11.29 Million | +8.00% |
| 2022-12-31 | $10.45 Million | -78.34% |
| 2021-12-31 | $48.25 Million | -18.90% |
| 2020-12-31 | $59.49 Million | -39.12% |
| 2019-12-31 | $97.73 Million | +1035.65% |
| 2018-12-31 | $-10.45 Million | -21.92% |
| 2017-12-31 | $-8.57 Million | -26.71% |
| 2016-12-31 | $-6.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyclerion Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27102000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cyclerion Therapeutics Inc Net Assets Breakdown (December 2025)
Cyclerion Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $280.11 Million | 3083.16% |
| Total Equity | $9.09 Million | 100.00% |
Cyclerion Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Income & Growth VCT
LSE:IGV
|
$2.25 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
$2.25 Million |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
$2.25 Million |
|
Afentra PLC
LSE:AET
|
$2.26 Million |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
$2.25 Million |
|
Invion Ltd
AU:IVX
|
$2.24 Million |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
$2.24 Million |
|
Majedie Investments
LSE:MAJE
|
$2.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyclerion Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,850,000 to 9,085,000, a change of 235,000 (2.7%).
- Net loss of 3,528,000 reduced equity.
- Share repurchases of 130,000 reduced equity.
- New share issuances of 1,375,000 increased equity.
- Other factors increased equity by 2,518,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.53 Million | -38.83% |
| Share Repurchases | $130.00K | -1.43% |
| Share Issuances | $1.38 Million | +15.13% |
| Other Changes | $2.52 Million | +27.72% |
| Total Change | $- | 2.66% |
Book Value vs Market Value Analysis
This analysis compares Cyclerion Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-4.93 | $23.94 | x |
| 2017-12-31 | $-6.28 | $23.94 | x |
| 2018-12-31 | $-7.65 | $23.94 | x |
| 2019-12-31 | $71.39 | $23.94 | x |
| 2020-12-31 | $39.14 | $23.94 | x |
| 2021-12-31 | $24.65 | $23.94 | x |
| 2022-12-31 | $4.81 | $23.94 | x |
| 2023-12-31 | $4.83 | $23.94 | x |
| 2024-12-31 | $3.51 | $23.94 | x |
| 2025-12-31 | $2.82 | $23.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyclerion Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -170.11%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.10x
- Recent ROE (-38.83%) is above the historical average (-90.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-62.88 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-93.07 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-114.21 Million |
| 2019 | -125.87% | -2729.27% | 0.02x | 1.91x | $-132.78 Million |
| 2020 | -130.78% | -3388.59% | 0.02x | 1.94x | $-83.75 Million |
| 2021 | -107.05% | -1555.63% | 0.06x | 1.23x | $-56.47 Million |
| 2022 | -421.72% | -14841.08% | 0.02x | 1.73x | $-45.12 Million |
| 2023 | -46.62% | 0.00% | 0.00x | 1.18x | $-6.39 Million |
| 2024 | -34.54% | -152.85% | 0.21x | 1.08x | $-3.94 Million |
| 2025 | -38.83% | -170.11% | 0.21x | 1.10x | $-4.44 Million |
Industry Comparison
This section compares Cyclerion Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyclerion Therapeutics Inc (CYCN) | $5.09 Million | 0.00% | 0.36x | $2.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more